NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: DIMETHAID RESEARCH INC.
TSE SYMBOL: DMX
OTC Bulletin Board SYMBOL: DMTHF
FEBRUARY 9, 1998
Dimethaid Research Announces Officers For Subsidiary
MARKHAM, ONTARIO--Rebecca Keeler, President and CEO of Dimethaid
Research Inc., announced today the appointment of Dr. Frederick N.
Ballantyne as President and Dr. Trevor A. Carmichael, Q.C. as
Corporate Secretary of Dimethaid Intenational Inc. of the
Barbados. "The appointment of these two eminently qualified
individuals puts into place the final piece of the necessary
infrastructure for us to license PENNSAID(TM) to an international
partner," said Mrs. Keeler.
Dr. Ballantyne received his medical degree from Syracuse
University in New York and completed his internship and residency
at the Montreal General Hospital and Rochester General Hospital in
New York. He was the Chief of Medicine and Medical Director for
the Kingstown General Hospital in St. Vincent for over 14 years
while also serving as the Assistant Dean of Clinical Studies at
St. George's University Medical School for much of that time. He
went on to become the Chief Medical Officer in St. Vincent, West
Indies for seven years. Presently, Dr. Ballantyne is the
Coordinator of Visiting Specialist Program and a Consultant in
Internal Medicine at the Kingstown General Hospital and a member
of the editorial board of the International Academy of Clinical
and Applied Thrombosis/Hemostatis.
Dr. Carmichael was called to the United Kingdom Bar and the
Barbados Bar in 1977. He is a member of the International Bar
Association, a Committee Member of the Inter-American Bar
Foundation as well as an associate member of the Canadian Bar
Association. He holds memberships in the International Tax
Planning Association and the International Fiscal Association; and
he is the Barbados Country Chairman of the International
Litigation Committee on Business Law of the International Bar
Association, as well as Deputy Secretary-General of that
Association. He was appointed by the Organization of American
States (OAS) to draft a new OAS Convention on International
Contracts. Dr. Carmichael is the Principal of Chancery Chambers,
a Barbados law firm engaged primarily in international and
domestic business law and international tax consulting.
Dimethaid International is a wholly owned subsidiary of Dimethaid
Research and holds the rights to the Company's patented
transdermal carrier in all jurisdictions outside of Canada. The
first product utilizing this technology is PENNSAID(TM), a
topically applied prescription lotion for the relief of pain from
osteoarthritis. Applications for marketing approval of
PENNSAID(TM) have been made to regulatory bodies in Canada, the
United Kingdom and the United States. Dimethaid Research is a
pharmaceutical company engaged in the development and
commercialization of innovative therapeutic products which work
with the body's own healing mechanisms.
-30-
|
